{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:03:27Z","timestamp":1793664207429,"version":"4.5.1"},"reference-count":108,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>While monoclonal antibodies (mAbs) continue to dominate the overall immunotherapy landscape, the field of T-cell-based therapeutics is rapidly evolving. Although chimeric antigen receptor T cells (CAR-T) and bispecific antibodies (BsAbs) currently represent the pillars of T-cell-directed therapy, the complexity of solid tumors demands a more diversified therapeutic arsenal. By combining antibody-mediated tumor targeting with the robust effector function of ex vivo expanded T cells, BsAb-armed T cells (BATs)-also referred to as Ex vivo Armed T cell (EATs)-provide a \u2018third way\u2019 that addresses the unmet needs of solid tumor immunotherapy. They can overcome the quantitative and qualitative deficiencies of endogenous immune effector cells in cancer patients. By offering personalized multi-antigen targetability and the prospect of off-the-shelf therapy, EATs have the potential to address critical challenges, such as poor tumor infiltration, immune escape via heterogeneity and target antigen loss, and treatment-related toxicities like cytokine release syndrome. In this review, we discuss the characteristics of EAT therapy, distinct from CAR-T and BsAb therapy, as an independent and alternative niche. We explore strategies to accelerate their clinical translation, encompassing BsAb optimization, modulation of the tumor microenvironment (TME) and cytokines, and simultaneous engagement of multiple antigens, which are essential for boosting EAT potency and overcoming the limitations of solid tumors. In this evolving landscape, EATs could play a unique and independent role, expanding the CAR-T and BsAb-dominated paradigm to address unmet clinical needs.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1822523","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T06:03:52Z","timestamp":1779775432000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Beyond the chimeric antigen receptor T cells and bispecific antibody duopoly: ex vivo armed T cells for solid tumors"],"prefix":"10.3389","volume":"17","author":[{"given":"Jeong A","family":"Park","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Inha University Hospital, Inha University College of Medicine","place":["Incheon, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nai-Kong V.","family":"Cheung","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Memorial Sloan Kettering Cancer Center","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2035","article-title":"Fda approval summary: Tisagenlecleucel for treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia","volume":"25","author":"O'Leary","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B2","volume-title":"Approved cellular and gene therapy products","year":"2025"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.5045\/br.2023.2023015","article-title":"Practical issues in CAR T-cell therapy","volume":"58","author":"Byun","year":"2023","journal-title":"Br"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102353","article-title":"Car-t cells in solid tumors: Challenges and breakthroughs","volume":"6","author":"Escobar","year":"2025","journal-title":"Cell Rep Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/moh.0000000000000548","article-title":"Mechanisms of failure of chimeric antigen receptor T-cell therapy","volume":"26","author":"Li","year":"2019","journal-title":"Curr Opin Hematol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02875-1","article-title":"Locoregional delivery of IL-13Ralpha2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial","volume":"30","author":"Brown","year":"2024","journal-title":"Nat Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01985","article-title":"Chimeric antigen receptor T cell therapy for pediatric B-ALL: Narrowing the gap between early and long-term outcomes","volume":"11","author":"Schultz","year":"2020","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1172\/jci125423","article-title":"Cd19 CAR T cell product and disease attributes predict leukemia remission durability","volume":"129","author":"Finney","year":"2019","journal-title":"J Clin Invest"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024166","article-title":"Second primary Malignancies after commercial CAR T-cell therapy: Analysis of the FDA adverse events reporting system","volume":"143","author":"Elsallab","year":"2024","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/nejmp2400209","article-title":"Secondary cancers after chimeric antigen receptor T-cell therapy","volume":"390","author":"Verdun","year":"2024","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02574-x","article-title":"Emerging T-cell lymphomas after CAR T-cell therapy","volume":"39","author":"Braun","year":"2025","journal-title":"Leukemia"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2309728","article-title":"Car+ T-cell lymphoma after cilta-cel therapy for relapsed or refractory myeloma","volume":"392","author":"Harrison","year":"2025","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/s1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001792","article-title":"Bites better than CAR T cells","volume":"5","author":"Subklewe","year":"2021","journal-title":"Blood Adv"},{"key":"B17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41408-024-00997-w","article-title":"Bispecific antibodies and CAR-T cells: Dueling immunotherapies for large B-cell lymphomas","volume":"14","author":"Trabolsi","year":"2024","journal-title":"Blood Cancer J"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.2012.126","article-title":"Drug transport across the blood-brain barrier","volume":"32","author":"Pardridge","year":"2012","journal-title":"J Cereb Blood Flow Metab"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33967","article-title":"Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia","volume":"128","author":"Aldoss","year":"2022","journal-title":"Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e009604","DOI":"10.1136\/jitc-2024-009604","article-title":"Novel tri-specific T-cell engager targeting IL-13Ralpha2 and EGFRvIII provides long-term survival in heterogeneous GBM challenge and promotes antitumor cytotoxicity with patient immune cells","volume":"12","author":"Park","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1586\/17512433.2013.811806","article-title":"An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma","volume":"6","author":"Gedeon","year":"2013","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-024-04564-y","article-title":"Phase I study targeting newly diagnosed grade 4 astrocytoma with bispecific antibody armed T cells (EGFR BATs) in combination with radiation and temozolomide","volume":"166","author":"Fadul","year":"2024","journal-title":"J Neuro-Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02692-8","article-title":"Anti-tumor and immune modulating activity of T cell induced tumor-targeting effectors (TITE)","volume":"70","author":"Thakur","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e002222","DOI":"10.1136\/jitc-2020-002222","article-title":"Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release","volume":"9","author":"Park","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-83","article-title":"Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies","volume":"13","author":"Zitron","year":"2013","journal-title":"BMC Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/s0169-409x(02)00178-3","article-title":"Bispecific antibody conjugates in therapeutics","volume":"55","author":"Cao","year":"2003","journal-title":"Adv Drug Delivery Rev"},{"key":"B27","doi-asserted-by":"publisher","first-page":"4765","DOI":"10.3390\/jcm13164765","article-title":"High-risk neuroblastoma challenges and opportunities for antibody-based cellular immunotherapy","volume":"13","author":"Persaud","year":"2024","journal-title":"J Clin Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-14-2280","article-title":"Targeted T-cell therapy in stage IV breast cancer: A phase I clinical trial","volume":"21","author":"Lum","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-22-1601","article-title":"Phase II trial of pembrolizumab and anti-CD3 x anti-HER2 bispecific antibody-armed activated T cells in metastatic castration-resistant prostate cancer","volume":"29","author":"Vaishampayan","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2020.1773201","article-title":"Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients","volume":"9","author":"Lum","year":"2020","journal-title":"Oncoimmunology"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1186\/2051-1426-3-s2-p56","article-title":"Vaccination with bispecific antibody armed T cells (BATC) in metastatic breast cancer patients and transfer of anti-breast cancer immunity in primed T cells after stem cell transplant: a proof of principle study","volume":"3","author":"Thakur","year":"2015","journal-title":"J Immunother Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e008744","DOI":"10.1136\/jitc-2023-008744","article-title":"Targeting refractory\/recurrent neuroblastoma and osteosarcoma with anti-CD3xanti-GD2 bispecific antibody armed T cells","volume":"12","author":"Yankelevich","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2013.133","article-title":"Multiple infusions of CD20-targeted T cells and low-dose IL-2 after SCT for high-risk non-Hodgkin's lymphoma: a pilot study","volume":"49","author":"Lum","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.12.030","article-title":"Targeting CD138-\/CD20+ clonogenic myeloma precursor cells decreases these cells and induces transferable antimyeloma immunity","volume":"22","author":"Lum","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24237","article-title":"Anti-CD3 x anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets","volume":"59","author":"Yankelevich","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29007","article-title":"Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy","volume":"136","author":"Cheng","year":"2015","journal-title":"Int J Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.10.6112","article-title":"Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity","volume":"166","author":"McCall","year":"2001","journal-title":"J Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2010.08.013","article-title":"Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging","volume":"38","author":"Orcutt","year":"2011","journal-title":"Nucl Med Biol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2016.1168557","article-title":"Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumors","volume":"5","author":"Cheng","year":"2016","journal-title":"Oncoimmunology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e133757","DOI":"10.1172\/jci.insight.133757","article-title":"Target arm affinities determine preclinical efficacy and safety of anti-HER2\/CD3 bispecific antibody","volume":"5","author":"Staflin","year":"2020","journal-title":"JCI Insight"},{"key":"B41","doi-asserted-by":"publisher","first-page":"14397","DOI":"10.1038\/s41598-021-93842-0","article-title":"Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning","volume":"11","author":"Haber","year":"2021","journal-title":"Sci Rep"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/1521-4141(200211)32:11<3102::aid-immu3102>3.0.co;2-c","article-title":"Optimizing anti-CD3 affinity for effective T cell targeting against tumor cells","volume":"32","author":"Bortoletto","year":"2002","journal-title":"Eur J Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0903296","article-title":"Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR","volume":"184","author":"Suzuki","year":"2010","journal-title":"J Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1182\/blood.V130.Suppl_1.2815.2815","article-title":"Generation of a half-life extended anti-CD19 BiTE\u00ae antibody construct compatible with once-weekly dosing for treatment of CD19-positive Malignancies","volume":"130","author":"Lorenczewski","year":"2017","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2502099","article-title":"Tarlatamab in small-cell lung cancer after platinum-based chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"N Engl J Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-14-0230-t","article-title":"Retargeting T cells to GD2 pentasaccharide on human tumors using bispecific humanized antibody","volume":"3","author":"Xu","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/b978-0-12-396962-0.00010-0","article-title":"Practical theoretic guidance for the design of tumor-targeting agents","volume":"503","author":"Wittrup","year":"2012","journal-title":"Methods Enzymol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"eaax1315","DOI":"10.1126\/scitranslmed.aax1315","article-title":"Interdomain spacing and spatial configuration drive the potency of IgG-[L]-scFv T cell bispecific antibodies","volume":"12","author":"Santich","year":"2020","journal-title":"Sci Transl Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.20496","article-title":"Variability of CD3 membrane expression and T cell activation capacity","volume":"78","author":"El Hentati","year":"2010","journal-title":"Cytometry B Clin Cytom"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-25-0159","article-title":"Targeting myeloid cells for cancer immunotherapy","volume":"13","author":"Blanchard","year":"2025","journal-title":"Cancer Immunol Res"},{"key":"B52","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s40164-024-00543-1","article-title":"Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies","volume":"13","author":"Zheng","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 challenges in cancer immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"},{"key":"B54","doi-asserted-by":"publisher","first-page":"3728","DOI":"10.1038\/s41467-022-31331-2","article-title":"MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma","volume":"13","author":"Tao","year":"2022","journal-title":"Nat Commun"},{"key":"B55","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3390\/cancers11070904","article-title":"Wnt signaling in cancer metabolism and immunity","volume":"11","author":"El-Sahli","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00689-z","article-title":"Clinical implications of T cell exhaustion for cancer immunotherapy","volume":"19","author":"Chow","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13045-021-01156-5","article-title":"Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response","volume":"14","author":"Park","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/srep23002","article-title":"Effects of systemically administered hydrocortisone on the human immunome","volume":"6","author":"Olnes","year":"2016","journal-title":"Sci Rep"},{"key":"B59","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/j.1365-2567.2007.02611.x","article-title":"Glucocorticoids exert opposing effects on macrophage function dependent on their concentration","volume":"122","author":"Lim","year":"2007","journal-title":"Immunology"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.41","article-title":"Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL","volume":"31","author":"Duell","year":"2017","journal-title":"Leukemia"},{"key":"B61","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12943-020-01234-1","article-title":"Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects","volume":"19","author":"Li","year":"2020","journal-title":"Mol Cancer"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0175-7","article-title":"Regulatory T cells in cancer immunosuppression - implications for anticancer therapy","volume":"16","author":"Togashi","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-12-191","article-title":"Ipilimumab augments antitumor activity of bispecific antibody-armed T cells","volume":"12","author":"Yano","year":"2014","journal-title":"J Transl Med"},{"key":"B64","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1097\/00002371-200109000-00002","article-title":"Cytokines and immune response in the tumor microenvironment","volume":"24","author":"Mocellin","year":"2001","journal-title":"J Immunother"},{"key":"B65","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nri1901","article-title":"The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design","volume":"6","author":"Waldmann","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0610115104","article-title":"The IL-15\/IL-15Ralpha on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cells","volume":"104","author":"Sato","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-377804","article-title":"IL-15 administered by continuous infusion to rhesus macaques induces massive expansion of CD8+ T effector memory population in peripheral blood","volume":"118","author":"Sneller","year":"2011","journal-title":"Blood"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-23-0910","article-title":"IL-15\/IL-15Ralpha-Fc-fusion protein XmAb24306 potentiates activity of CD3 bispecific antibodies through enhancing T-cell expansion","volume":"23","author":"Li","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.85974","article-title":"TGF-beta and VEGF cooperatively control the immunotolerant tumor environment and the efficacy of cancer immunotherapies","volume":"1","author":"Courau","year":"2016","journal-title":"JCI Insight"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.10.012","article-title":"TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance","volume":"8","author":"Thomas","year":"2005","journal-title":"Cancer Cell"},{"key":"B71","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41571-020-0403-1","article-title":"TGFbeta biology in cancer progression and immunotherapy","volume":"18","author":"Derynck","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-18-2019","article-title":"A new switch for TGFbeta in cancer","volume":"79","author":"Yeh","year":"2019","journal-title":"Cancer Res"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1100\/tsw.2002.873","article-title":"Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells","volume":"7","author":"Gorelik","year":"2001","journal-title":"Nat Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2024.2338558","article-title":"Combination of T cell-redirecting strategies with a bispecific antibody blocking TGF-beta and PD-L1 enhances antitumor responses","volume":"13","author":"Tapia-Galisteo","year":"2024","journal-title":"Oncoimmunology"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2850-3","article-title":"Cancer immunotherapy via targeted TGF-beta signalling blockade in T(H) cells","volume":"587","author":"Li","year":"2020","journal-title":"Nature"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.5ru0222-082r","article-title":"Direct and indirect regulation of the tumor immune microenvironment by VEGF","volume":"111","author":"Zhang","year":"2022","journal-title":"J Leukoc Biol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-12-2325","article-title":"VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer","volume":"73","author":"Terme","year":"2013","journal-title":"Cancer Res"},{"key":"B78","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","article-title":"Angiogenic signaling pathways and anti-angiogenic therapy for cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduction Targeted Ther"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.068","article-title":"Phase III, randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR- or ALK-mutated non-small-cell lung cancer (ATTLAS, KCSG-LU19-04)","volume":"42","author":"Park","year":"2024","journal-title":"J Clin Oncol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"e005583","DOI":"10.1136\/jitc-2022-005583","article-title":"Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice","volume":"11","author":"Dong","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B82","doi-asserted-by":"publisher","first-page":"e006680","DOI":"10.1136\/jitc-2023-006680","article-title":"Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody","volume":"11","author":"Park","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.02.002","article-title":"High endothelial venules in cancer: regulation, function, and therapeutic implication","volume":"41","author":"Vella","year":"2023","journal-title":"Cancer Cell"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3836","article-title":"De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors","volume":"18","author":"Johansson-Percival","year":"2017","journal-title":"Nat Immunol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.12.006","article-title":"Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1(+) T lymphocyte niches through a feed-forward loop","volume":"40","author":"Hua","year":"2022","journal-title":"Cancer Cell"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)02722-3","article-title":"Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China","volume":"405","author":"Xiong","year":"2025","journal-title":"Lancet"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2019.12.012","article-title":"PD-1 imposes qualitative control of cellular transcriptomes in response to T cell activation","volume":"77","author":"Shimizu","year":"2020","journal-title":"Mol Cell"},{"key":"B88","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1172\/jci131246","article-title":"Tandem CAR T cells targeting HER2 and IL13Ralpha2 mitigate tumor antigen escape","volume":"126","author":"Hegde","year":"2016","journal-title":"J Clin Invest"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdac185","article-title":"Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13Ralpha2 are effective against heterogeneous glioblastoma","volume":"5","author":"Schmidts","year":"2023","journal-title":"Neuro-Oncol Adv"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005278","article-title":"Optimized tandem CD19\/CD20 CAR-engineered T cells in refractory\/relapsed B-cell lymphoma","volume":"136","author":"Tong","year":"2020","journal-title":"Blood"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-23-0408","article-title":"Dual CAR-T cells targeting CD19 and CD37 are effective in target antigen loss B-cell tumor models","volume":"23","author":"Imai","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"B93","doi-asserted-by":"publisher","first-page":"e003771","DOI":"10.1136\/jitc-2021-003771","article-title":"Overcoming tumor heterogeneity by ex vivo arming of T cells using multiple bispecific antibodies","volume":"10","author":"Park","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.bcd-20-0020","article-title":"Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape-driven relapse in multiple myeloma","volume":"1","author":"Fernandez de Larrea","year":"2020","journal-title":"Blood Cancer Discov"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05778-2","article-title":"Co-opting signalling molecules enables logic-gated control of CAR T cells","volume":"615","author":"Tousley","year":"2023","journal-title":"Nature"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.12.7647","article-title":"T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity","volume":"173","author":"Chmielewski","year":"2004","journal-title":"J Immunol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"14366","DOI":"10.1038\/s41598-017-14749-3","article-title":"Micromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity","volume":"7","author":"Park","year":"2017","journal-title":"Sci Rep"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.8b09198","article-title":"Multivalent ligand binding to cell membrane antigens: defining the interplay of affinity, valency, and expression density","volume":"141","author":"Csizmar","year":"2019","journal-title":"J Am Chem Soc"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2017.1320625","article-title":"Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2","volume":"6","author":"Hoseini","year":"2017","journal-title":"Oncoimmunology"},{"key":"B100","doi-asserted-by":"publisher","first-page":"a041574","DOI":"10.1101\/cshperspect.a041574","article-title":"Immunotherapies for childhood cancer","volume":"15","author":"Park","year":"2025","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2020.00312","article-title":"Targeting cancer stem cells by genetically engineered chimeric antigen receptor T cells","volume":"11","author":"Alhabbab","year":"2020","journal-title":"Front Genet"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-04-493361","article-title":"CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma","volume":"122","author":"Casucci","year":"2013","journal-title":"Blood"},{"key":"B103","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13046-019-1147-6","article-title":"Anti-CD166\/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma","volume":"38","author":"Wang","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-02891-x","article-title":"Simultaneously target of normal and stem cells-like gastric cancer cells via cisplatin and anti-CD133 CAR-T combination therapy","volume":"70","author":"Han","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2013.07.006","article-title":"Cytokine-induced killer (CIK) cells bound with anti-CD3\/anti-CD133 bispecific antibodies target CD133(high) cancer stem cells in vitro and in vivo","volume":"149","author":"Huang","year":"2013","journal-title":"Clin Immunol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-14-2415","article-title":"Effective eradication of glioblastoma stem cells by local application of an AC133\/CD133-specific T-cell-engaging antibody and CD8 T cells","volume":"75","author":"Prasad","year":"2015","journal-title":"Cancer Res"},{"key":"B107","doi-asserted-by":"publisher","first-page":"6580","DOI":"10.1038\/s41467-025-61647-8","article-title":"ST2\/IL-33 axis blockade inhibits regulatory T cell cytotoxicity towards CD8 T cells in the leukemic niche","volume":"16","author":"Jiang","year":"2025","journal-title":"Nat Commun"},{"key":"B108","doi-asserted-by":"publisher","first-page":"6369","DOI":"10.1038\/s41467-025-61567-7","article-title":"Dual targeting of tumoral cells and immune microenvironment by blocking the IL-33\/IL1RL1 pathway","volume":"16","author":"Fu","year":"2025","journal-title":"Nat Commun"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1822523\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T06:03:54Z","timestamp":1779775434000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1822523\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":108,"alternative-id":["10.3389\/fimmu.2026.1822523"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1822523","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"article-number":"1822523"}}